Clinical Trial Update: Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sacituzumab govitecan in combination with atropine to improve tolerability in advanced breast cancers, including HR+/HER2- a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Atropine (atropine)
• Sacituzumab Govetican (sacituzumab govitecan)

Snippet

Sponsor: MedSIR | Conditions: Breast Cancer, Advanced HR+/HER2- Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING